Annual Report

Overview

The report highlights Starpharma's expanded research partnerships with MSD and Genentech, continued progress across three internal Phase 2 oncology programs, and broader VIRALEZE commercial reach through new launches and registrations that took the product to more than 35 countries. It also presents the company's ESG framework and notes that ESG Report 2023 was released alongside the Annual Report. The year included Great Place to Work certification for the 2022-23 period and continued development of Starpharma's oncology, radiodiagnostic and ADC pipeline.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023
Period: Ends 30 June 2023
Publication date: 24 August 2023
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services